LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Heron Therapeutics Inc

Închisă

SectorSănătate

0.82 -4.65

Rezumat

Modificarea prețului

24h

Curent

Minim

0.81

Maxim

0.86

Indicatori cheie

By Trading Economics

Venit

15M

-3M

Vânzări

2.4M

41M

EPS

-0.02

Marjă de profit

-7.278

Angajați

128

EBITDA

13M

-792K

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+417.24% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-49M

169M

Deschiderea anterioară

5.47

Închiderea anterioară

0.82

Sentimentul știrilor

By Acuity

50%

50%

171 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 mar. 2026, 22:51 UTC

Câștiguri

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar. 2026, 21:40 UTC

Achiziții, Fuziuni, Preluări

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar. 2026, 20:31 UTC

Câștiguri

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar. 2026, 23:49 UTC

Market Talk
Evenimente importante

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar. 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar. 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar. 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar. 2026, 22:36 UTC

Câștiguri

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar. 2026, 22:24 UTC

Câștiguri

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar. 2026, 22:23 UTC

Câștiguri

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar. 2026, 22:23 UTC

Câștiguri

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar. 2026, 21:58 UTC

Câștiguri

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar. 2026, 21:55 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

18 mar. 2026, 21:55 UTC

Market Talk
Câștiguri

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar. 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar. 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar. 2026, 21:00 UTC

Evenimente importante

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar. 2026, 20:58 UTC

Câștiguri

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar. 2026, 20:41 UTC

Câștiguri

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar. 2026, 20:29 UTC

Câștiguri

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar. 2026, 20:25 UTC

Câștiguri

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar. 2026, 20:17 UTC

Câștiguri

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar. 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar. 2026, 20:09 UTC

Câștiguri

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar. 2026, 20:07 UTC

Câștiguri

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar. 2026, 20:06 UTC

Câștiguri

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar. 2026, 20:04 UTC

Câștiguri

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar. 2026, 20:04 UTC

Câștiguri

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar. 2026, 20:04 UTC

Câștiguri

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar. 2026, 20:03 UTC

Câștiguri

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

417.24% sus

Prognoză pe 12 luni

Medie 4.5 USD  417.24%

Maxim 6 USD

Minim 3 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

171 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat